The study will be a single center, Phase I safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung disease. It will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc.
The study outcomes will be safety – to determine pharmacokinetics and biodistribution of PulmoBind in humans and to perform dosimetric evaluation, and efficacy – to evaluate the ability of PulmoBind to allow lung perfusion imaging in humans. Pulmo BioTech expects this work to be completed by late summer 2008.